Chiltern Expands North American Operations with a New Office in Illinois
Chiltern International announced that it has opened a new office in the Chicago area, specifically in Bannockburn, IL.
Barry Simms, Chiltern’s Country Manager, North America, commented, “Chiltern continues to look for opportunities to increase our strategic footprint and we are very excited about our expansion to the greater Chicago area. Our new office is well situated to support our efforts to recruit top-notch staff and be strategically near our clients.”
“We are extremely pleased by the success we have had attracting high-qualified staff to our Bannockburn office, and we welcome our new colleagues to the team,” Dr. Jim Esinhart, Sr. Executive VP, Global Scientific Services, Chiltern, stated. “Our new office supports Chiltern’s mission to deliver high quality services around the world, while demonstrating our commitment to clients’ needs.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
